Navigation Links
Menopause-Like Woes Hinder Breast Cancer Treatment: Study

FRIDAY, April 12 (HealthDay News) -- Hot flashes and other unpleasant side effects are a major reason one-quarter of breast cancer patients do not start or do not complete their recommended hormone-blocking therapy, a new study finds.

Five years of daily pills -- either tamoxifen or aromatase inhibitors -- is recommended for many women whose breast cancer expresses the hormones estrogen or progesterone. The drugs have been shown to reduce the risk of cancer returning and to extend survival.

Despite such benefits, this study of more than 700 breast cancer patients in Detroit and Los Angeles who were eligible for hormone therapy found that about 11 percent never started treatment and 15 percent stopped it early.

Unpleasant, menopause-type side effects, such as vaginal dryness, hot flashes or joint pain, were the most common reasons women either stopped or never started the therapy.

"We need to develop better ways of supporting women through this therapy," lead study author Christopher Friese, an assistant professor at the University of Michigan School of Nursing, said in a university news release.

Those most likely to complete their hormone therapy were patients who were most worried about their cancer returning and those who already took medication regularly, according to the study, which was published online March 31 in the journal Breast Cancer Research and Treatment.

Patients least likely to begin hormone therapy included those who received less information about hormone therapy, which suggests that doctors need to properly educate patients before treatment begins, the researchers said.

Women who saw a breast cancer surgeon instead of a medical oncologist as their primary follow-up also were less likely to begin hormone therapy.

"It was particularly interesting that greater fear of recurrence was associated in our patient sample with greater adherence to endocrine therapy," study senior study author Dr. Jennifer Griggs, a professor of internal medicine at the University of Michigan Medical School.

"We don't want our patients living under a cloud of fear, so we need to develop creative ways to both reassure and motivate them," said Griggs, a medical oncologist. "This means providing better education about the importance of staying on these medications and partnering with primary care and cancer doctors to help patients manage symptoms."

More than 234,000 Americans will be diagnosed with breast cancer this year and more than 40,000 will die from the disease, the American Cancer Society estimates.

More information

The U.S. National Cancer Institute has more about breast cancer treatment.

-- Robert Preidt

SOURCE: University of Michigan Comprehensive Cancer Center, news release, April 9, 2013

Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Incarceration, marijuana use and suicide attempts may hinder liver transplant eligibility
2. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Improves the My Diet Doc Health Questionnaire; Better Identifying Internal Factors that May Hinder Fast Weight Loss
3. Negative stereotypes about boys hinder their academic achievement
4. Study finds health departments hindered in addressing health concerns from animal production sites
5. National Cancer Centre Singapore scientists discover p53 mutation hinders cancer treatment response
6. Overestimation of abortion deaths in Mexico hinders maternal mortality reduction efforts
7. No Truth to Candidates Claim That Rape Hinders Pregnancy, Experts Say
8. Obesity Might Hinder Treatment of Some Breast Cancers
9. Parents work-life stress hinders healthy eating
10. Depressed Moms May Hinder Babies Sleep
11. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: